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Melanoma is the most common form of skin cancer. Given its high mortality, the interest
in the search of preventive measures, such as dietary factors, is growing significantly.
In this study we tested, in vitro and in vivo, the potential anti-cancer effect of the
acetyl deacylasadisulfide (ADA), a vinyl disulfide compound, isolated and purified from
asafoetida a foul-smelling oleo gum-resin of dietary and medicinal relevance. ADA
markedly suppressed proliferation of human melanoma cell lines by inducing apoptosis.
Moreover, treatment of melanoma cells with ADA reduced nuclear translocation and
activation of NF-κB, decreased the expression of the anti-apoptotic proteins c-FLIP,
XIAP, and Bcl-2 and inhibited the phosphorylation and activation of both AKT and
ERK proteins, two of the most frequently deregulated pathways in melanoma. Finally,
the results obtained in vitro were substantiated by the findings that ADA significantly
and dose-dependently reduced lung metastatic foci formation in C57BL/6 mice. In
conclusion, our findings suggest that ADA significantly inhibits melanoma progression
in vivo and could represent an important lead compound for the development of new
anti-metastatic agents.
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INTRODUCTION
Hydrogen sulfide (H2S) is a gaseous signaling molecule that plays important roles in a variety of
biological functions, in health and disease (Szabo, 2007; Kimura, 2011; Whiteman et al., 2011;
Wang, 2012). The physiological production of H2S is mainly deputed to the activity of three
enzymes: Cystathionine-β-synthase (CBS), cystathionine-γ-lyase (CSE), and 3-mercaptopyruvate
sulfurtransferase (3-MST). Recently endogenous generated H2S has been involved in the regulation
of cancer biological processes and, according to the cancer type, different roles can be ascribed to
the molecule as recently reviewed (Szabo, 2016). In colorectal cancer, ovarian cancer, and breast
cancer an increase in the expression of CBS in cancer cells has been associated to the promotion of
cell proliferation and cellular bioenergetics (Hellmich and Szabo, 2015). In human melanoma, H2S
generated by over-expressed CSE appears to be involved in the progression of the disease (Panza
et al., 2015). While inhibition of H2S biosynthesis produces anticancer effects, many reports show
that H2S donors, of either natural or chemical origin, exert anticancer actions in vitro and in vivo
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(Hellmich et al., 2015; Panza et al., 2015). Thus, it has been
hypothesized that low (endogenous) levels of H2S tend to
promote, while higher levels released from donors (exogenous),
tend to inhibit cancer cell proliferation (Hellmich et al., 2015).
Ferula assa-foetida is the main source of asafoetida, an
oleo-gum resin obtained by incision of the roots of various
plants from the genus Ferula (family Umbelliferae) native to
Central Asia, Afghanistan and Iran (Mahendra and Bisht, 2012).
Asafoetida chiefly subsume resin (40–65%), gum (20–25%), and
volatile oil (3–17%) the latter consisting of disulfides as its
major components that are responsible for the characteristic
odor of asafoetida (Iranshahy and Iranshahi, 2011). Asafoetida
is a popular ingredient in the Indian cuisine and it is also
used in traditional medicine for treating many human diseases
such as asthma, gastro-intestinal disorders, influenza, and more
recently, a cancer chemopreventive role for asafoetida has been
described (Kim et al., 2011; Kiani et al., 2015; Oh et al., 2015).
Different mechanisms seem to impact on this activity such as
radical scavenging activity of sulfur-containing compounds even
if the exact mechanism through which asafoetida behaves as ant-
tumor agent has yet to be elucidated. In the present study, we
have isolated and purified from asafoetida a new H2S-donor,
ADA, studied and clarified its mechanism of action in vitro and
demonstrated its anti-tumoral activity in vivo.
METHODS
Plant Material and Isolation of Vinyl
Disulfides
The latex of F. asafoetida was collected by incision of the
root collar from plants growing in Jandagh (Isfahan, Iran)
at an altitude of 1500m above sea level. The plant material
was identified by Dr. Mohammad-Reza Kanani, Department of
Biology, Medicinal Plants and Drugs Research Institute, Shahid
Beheshti University, Tehran, Iran, where a voucher specimen is
kept (School of Pharmacy, Isfahan, No. 5729). The latex (100
g) was dried and extracted with acetone (2 × 1 L) for 2 days
with continuous shaking to afford a gummy residue (30 g), that
was fractionated by gravity column chromatography on silica
gel and further purified by HPLC to obtain pure compounds as
previously described (Shokoohinia et al., 2013).
Reagents and Cell Culture
Normal human epidermal melanocytes (NHEM) were purchased
from Lonza (Walkersville, MD, USA) and were grown in
Melanocyte growth medium 2 (Lonza). The melanoma cells
lines B16/F10, Sk-Mel-5, and Sk-Mel-28 were purchased from
IRCCS AOU San Martino—IST (Genova, Italy), A375 from
Sigma-Aldrich (Milan, Italy), and WM3060 and WM983A
were purchased from Rockland (Limerick, Ireland). B16/F10,
Sk-Mel-5, Sk-Mel-28, and A375 were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% fetal bovine
serum, 2 mmol/L L-glutamine, 100 µmol/L non-essential amino
Abbreviations: H2S, hydrogen sulfide; ADA, acetyl deacylasadisulfide;
PDA, propionyl deacylasadisulfide; FSA, foetisulfide A; ARDA, arachyl
deacylasadisulfide; DA, deacylasadisulfide; MEF, methoxylatifolone.
acids, penicillin (100 U/mL), streptomycin (100 µg/mL), and 1
mmol/L sodium pyruvate (all from Sigma-Aldrich, Milan, Italy).
WM3060 and WM983A were cultured in Tumor Specialized
Media (1:5 Leibovitz’s—MCDB153), containing 2% Inactivated
FBS and 1.68 mM CaCl2. Cells were grown at 37
◦C in
a humidified incubator under 5% CO2. The cell line PES
43 was isolated from a lung metastases of a patient from
the National Cancer Institute, G. Pascale Foundation (Scala
et al., 2006) and cultured in Iscove’s modified Dulbecco’s
medium (Cambrex Bioscience, Verviers, Belgium) supplemented
with heat-inactivated 10% fetal bovine serum, penicillin, and
streptomycin (100 units/mL each). ADA was diluted in DMSO to
produce a stock solution of 10 mM for in vitro experiments. All
cell lines used in this study were characterized by the cell bank
were they were purchased.
Proliferation Assay
Cell proliferation was measured by the 3-[4,5-dimethyltiazol-
2yl]-2,5 diphenyl tetrazolium bromide (MTT) assay. The
melanoma cells (A375, SK-Mel-5, SK-Mel-28, PES43, B16/F10,
WM3060, and WM983A) and the NHEM cells were seeded
on 96-well plates (1 × 104 cells/well) and treated with ADA
or with the other compounds: Propionyl deacylasadisulfide
(PDA); methoxylatifolone (MEF); foetisulfide A (FSA); arachyl
deacylasadisulfide (ARDA); deacylasadisulfide (DA)]; (10-30-100
µM) for 24–48–72 h before adding 25 µl of MTT (Sigma, Milan,
Italy) (5 mg/ml in saline). Cells were incubated for additional
3 h at 37◦C. Thereafter, cells were lysed and dark blue crystals
were solubilized with a solution containing 50% (vol/vol) N,N-
dimethyl formamide, 20% (wt/vol) sodium dodecylsulfate with
an adjusted pH of 4.5. The OD of each well was measured with
a microplate spectrophotometer (TitertekMultiskan MCC/340)
equipped with a 620-nm filter.
Amperometric Measurement of Hydrogen
Sulfide Realease from ADA
The characterization of the potential H2S-generating properties
of the tested compound ADA has been carried out by an
amperometric approach, through the Apollo-4000 free radical
analyzer (WPI) detector and H2S-selective mini-electrodes. The
experiments have been carried out at room temperature (20◦C).
Following themanufacturer’s instructions, a “PBS buffer 10x” was
prepared (NaH2PO4·H2O 1.28 g, Na2HPO4.12H2O 5.97 g, NaCl
43.88 g in 500 ml H2O) and stocked at 4
◦C. Immediately before
the experiments, the “PBS buffer 10x” was diluted using distilled
water (1:10) to obtain the assay buffer and the pH adjusted
to 7.4. The H2S-selective mini-electrode was equilibrated in 10
ml of the assay buffer, until the recovery of a stable baseline.
Then, 100 µl of a DMSO solution of ADA was added (the
final concentration of the tested compound was 100 µM; the
final concentration of DMSO in the assay buffer was 1%). The
eventual generation of H2S was observed for 20 min. Preliminary
experiments demonstrated that DMSO 1% did not produce any
interference on the amperometric recording. When required by
the experimental protocol, the nucleophil L-cysteine (4 mM) was
added 10 min before the addition of ADA. L-Cysteine did not
produce any amperometric response. The correct relationship
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between the amperometric currents (recorded in pA) and the
corresponding concentrations of H2S was previously determined
by suitable calibration curves, which were obtained by the use of
increasing concentrations of NaHS (1, 3, 5, and 10µM) at pH 4.0.
Flow Cytometry
Apoptosis was detected with an Annexin V-FITC kit purchased
from BD Pharmingen (San Diego, CA, USA) according to the
manufacturer’s instructions. PES 43 cells were seeded in 35
mm culture dishes and allowed to attach overnight. The cells
were treated with ADA (100 µM) for 24–48–72 h, collected,
and washed twice with PBS. Samples were then taken to
determine baseline and drug-induced apoptosis by Annexin
V-FITC/Propidium Iodide (PI) (Beckman Coulter; Brea, CA)
double staining or PI staining and flow cytometry analysis using
a FACSCanto II 6-color flow cytometer (Becton Biosciences, San
Jose, CA), as described previously (Ianaro et al., 2009). To detect
early and late apoptosis, both adherent and floating cells were
harvested together and resuspended in annexin V binding buffer
(10 mM HEPES/NaOH pH 7.4, 140 mM NaCl, 2.5 mM CaCl2)
at a concentration of 106 cells/mL. Subsequently, 5 µL of FITC-
conjugated Annexin V and 5 µL of PI were added to 100 µL of
the cell suspension (105 cells). The cells were incubated for 15
min at room temperature in the dark. Finally, 400 µL of annexin
V binding buffer was added to each tube. A minimum of 50000
events for each sample were collected and data were analyzed
using FacsDiva software (Becton Biosciences).
Preparation of Cellular Extracts and
Western Blot Analysis
PES 43 and A375 cells were treated with ADA 100 µM for
15–30–60’or for 3–6–24–48 h. Whole-cell or nuclear extracts
were prepared as previously described (Ialenti et al., 2005; Panza
et al., 2016). The protein concentration was measured by the
Bradford method (Bio-Rad, Milan, Italy). Equal amounts of
protein (40 µg/sample) from whole or nuclear cell extracts
were separated by sodium dodecylsulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and blotted onto a nitrocellulose
membranes (Trans-Blot Turbo Transfer Starter System, Biorad).
The membranes were blocked for 2 h in 5% low-fat milk in
PBS with 0.1% Tween 20 (PBST) at room temperature. Then
the filters were incubated with the following primary antibodies:
IκBα (sc-1643 Cruz Biotechnology, Santa Cruz, CA; diluted
1:200); Bcl-2 (2876, Cell Signaling, USA; diluted 1:1000), caspase
3 (9662, Cell Signaling, USA; diluted 1:1000), PARP (9542,
Cell Signaling, USA; diluted 1:1000), p44/42 MAPK (Erk1/2)
(9102, Cell Signaling, USA; diluted 1:1000), Phospho-p44/42 Erk
MAPK (Erk1/2, Thr202/Tyr204) XP (4370, Cell Signaling, USA;
diluted 1:2000), AKT (9272, Cell Signaling, USA; diluted 1:1000),
Phospho-AKT (Ser473) XP (4060, Cell Signaling, USA; diluted
1:2000), c-FLIP (06-864, Millipore; diluted 1µg/ml); XIAP (R&D
System, Minneapolis; 1 µg/ml); NF-κB p65 (F-6): (sc-8008 Santa
Cruz Biotechnology, Santa Cruz, CA; diluted 1:200); β-actin
(Santa Cruz Biotechnology, Santa Cruz, CA; diluted 1:1000),
GAPDH (2118, Cell Signaling, USA; diluted 1:1000) overnight at
4◦C. The membranes were washed 3 times with PBST and then
incubated with horseradish peroxidase-conjugated antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA; diluted 1:2000) for 2
h at room temperature. The immune complexes were visualized
by the ECL chemiluminescence method and acquired by the
Image Quant 400 system (GE Healthcare).
Invasion Assay
The assay was performed using chambers with polycarbonate
filters with 8-µm nominal pore size (Millipore, USA) coated on
the upper side with Matrigel (Becton Dickinson Labware, USA)
as previously described (Ivanov et al., 2003). Briefly, the chambers
were placed into a 24-well plate and melanoma cells (2.5 ×
105/mL) were plated in the upper chamber, with or without ADA
(10–30 µM), in serum-free DMEM. After the incubation period
(16 h), the filter was removed, and non-migrant cells on the
upper side of the filter were detached with the use of a cotton
swab. Filters were fixed with 4% formaldehyde for 15 min, and
cells located in the lower filter were stained with 0.1% crystal
violet for 20 min and then washed with PBS. The filters were
examined microscopically and cellular invasion was determined
by counting the number of stained cells on each filter in at least 4–
5 randomly selected fields. Resultant data are presented as a mean
of invaded cells ± SEM /microscopic field of three independent
experiments.
Animals
The experimental procedures, according to Italian (DL 26/2014)
and European (n. 63/2010/UE) regulations on the protection of
animals used for experimental and other scientific purposes, were
approved by the Italian Ministry. All studies involving animals
are reported in accordance with the ARRIVE guidelines for
reporting experiments involving animals (Kilkenny et al., 2010;
McGrath et al., 2010). Mice were observed daily and humanely
euthanized by CO2 inhalation if a solitary subcutaneous tumor
exceeded 1.5 cm in diameter or mice showed signs referable
to metastatic cancer. All efforts were made to minimize
suffering. Female C57BL/6 mice (18−20 g) were purchased
from Charles River Laboratories, Inc. Mice were housed at the
Animal Research Facility of the Department of Pharmacy of the
University of Naples Federico II.
Tumor Metastasis Assay
B16/F10 (5 × 105) murine melanoma cells were collected in PBS
and injected via tail vein into syngeneic C57BL/6J mice. The
mice were equally randomized into three groups (8 mice/group):
0.9% normal saline control group, ADA 5 mg·kg−1 group, ADA
50 mg·kg−1 group. Starting on the 1st day after tumor cell
inoculation, test compounds were given orally every day for 14
days. Then the mice were weighed and sacrificed. The lungs were
removed and washed with PBS. The percentage of metastatic area
was calculated using ImageJ software (ImageJ).
Data Analysis
Data are expressed as mean ± SEM of n experiments. Data
were analyzed and presented using GRAPHPAD PRISM software
(GraphPad). Significance was determined using Student’s 2-tailed
t-test. Results were considered significant at P-values ≤ 0.05
and are labeled with a single asterisk. In addition, P-values ≤
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0.01 and 0.001 are designated with double and triple asterisks,
respectively.
RESULTS
ADA Suppresses the Proliferation of
Human Melanoma Cells in Vitro
In preliminary experiments, the disulfide compounds obtained
from asafoetida were evaluated for their anti-proliferative activity
on human melanoma cells A375 (Figure 1). After an initial
screening, we found that all the sulfur-containing compounds
ADA, PDA, FSA, ARDA, and DA inhibited the proliferation of
melanoma cells although with different potency (Figure 1). On
the other hand, the structurally unrelated MEF was practically
inactive. Therefore, the disulfide group is essential for the anti-
proliferative effect. Among the active compounds ADA and
PDA showed similar activity on the human melanoma cell
line A375 (IC50 51.4 and 54.6 µM, respectively). The selection
of ADA for further investigation was based on the relative
abundance of this metabolite in the plant, the higher availability
for pharmacological evaluation as well as the presence of a clear
concentration-related effect as compared to PDA.
ADA also inhibited the proliferation of all the other human
melanoma cell lines employed in this study, namely SK-Mel-
5, SK-Mel-28, WM983A, and PES43 cell lines, all carrying
the BRAFv600E mutation and the WM3060 cell line wild type
for BRAF, without affecting NHEM proliferation (Table 1). A
marked inhibition of cell proliferation was observed also in
the murine cell line B16/F10 after incubation with increasing
concentration of ADA (Table 1). Among the human cell lines
employed the high metastatic PES43 and A375 were the most
sensitive to the anti-proliferative activity of ADA. In fact, as
shown in Table 1 increasing concentration of ADA (10-30-100
µM) inhibited PES43 proliferation at 72 h by 38, 61, and 71%,
respectively (P < 0.001, n= 5) and A375 cell proliferation by 28,
54, and 76% respectively (P< 0.001, n= 5). Thus, these cell lines
were selected for the molecular studies.
ADA Induces Apoptosis and Activation of
Caspase-3 in Human Melanoma Cells
To verify if the anti-proliferative effect of ADA was related to its
ability to induce apoptosis of cancer cells, the cytofluorimetric
assay, with Annexin V/PI dual staining, was carried out on
melanoma cells PES43 and A375. This dual staining distinguishes
between unaffected (unlabeled; quadrant 3, Q3), early apoptotic
FIGURE 1 | Disulfide compounds from asafetida inhibit the proliferation of human melanoma cells A375. A375 cells were treated with increasing
concentration (10–30–100 µM) of several disulfide compounds (propionyl deacylasadisulfide, PDA; acetyl deacylasadisulfide, ADA; foetisulfide A, FSA; arachyl
deacylasadisulfide, ARDA; deacylasadisulfide, DA) and one no sulfur-containing compound (methoxylatifolone, MEF). Growth inhibition was measured at 72 h using
the MTT assay and is expressed as OD values. All the compounds tested, with the only exception of the MEF, inhibited the proliferation of melanoma cells although
with different potency. Experiments were run in triplicate, each performed in quadruplicate (*P < 0.05; ***P < 0.001 vs. control [CTRL]).
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(Annexin V positive; quadrant 4, Q4), late apoptotic (Annexin V
positive, PI positive; quadrant 2, Q2), and necrotic (PI positive;
quadrant 1, Q1) cells. Treatment of PES 43 and A375 cells
TABLE 1 | Anti-proliferative effect of ADA on different human melanoma
cell lines.
Cell line CTRL ADA 10 µM ADA 30 µM ADA 100 µM
NHEM 0.230 ± 0.01 0.233 ± 0.002 0.223 ± 0.003 0.219 ± 0.01
PES43 0.532 ± 0.05 0.329 ± 0.03*** 0.208 ± 0.008*** 0.154 ± 0.003***
A375 0.641 ± 0.02 0.467 ± 0.02*** 0.297 ± 0.03*** 0.155 ± 0.002***
Sk-Mel-28 0.520 ± 0.01 0.504 ± 0.02 0.485 ± 0.02 0.115 ± 0.002***
Sk-Mel-5 0.309 ± 0.007 0.291 ± 0.001 0.252 ± 0.01 0.07 ± 001***
WM983A 0.218 ± 0.002 0.201 ± 0.005 0.195 ± 0.003 0.093 ± 0.002***
WM3060 0.223 ± 0.003 0.190 ± 0.004 0.173 ± 0.004** 0.118 ± 0.002***
B16F10 1.0 ± 0.01 0.757 ± 0.01*** 0.41 ± 0.005*** 0.101 ± 0.001***
NHEM, A375, Sk-Mel-5, Sk-Mel-28, PES43, WM3060, WM968A, and B16/F10 cells
were treated with increasing concentration (10-30-100 µM) of ADA. Growth inhibition
was measured at 72 h using the MTT assay and is expressed as OD values ± SEM.
Experiments were run in triplicate, each performed in quadruplicate (**P < 0.01; ***P <
0.001 vs. control [CTRL]).
for 24–48–72 h with ADA (100 µM) resulted in a significant
and time–dependent induction of apoptosis (Figures 2A,B,D,E).
The pro-apoptotic effect of ADA was confirmed by a time-
dependent cleavage of caspase 3, the main effector caspase, and
of its substrate poly (adenosine diphosphate-ribose) polymerase
(PARP) (Figures 2C,F).
ADA Inhibits NF-κB Activation and
Down-Regulates NF-κB Dependent
Anti-Apoptotic Genes
It has been reported that in melanoma constitutive activation of
NF-κB confers tumor survival capacity and apoptosis avoidance
(Ueda and Richmond, 2006). In order to analyze if the inhibition
of apoptosis induced by ADA was involving the NF-κB pathway,
PES 43 and A375 cells were treated with ADA 100 µM for 15,
30, and 60 min and western blot analysis was carried out on
cellular extracts. As shown in Figures 3A,E an inhibition of IκBα
degradation at the earliest time points following ADA incubation
was observed. This effect was abided by the inhibition of NF-
κB nuclear translocation as demonstrated by a reduction in band
intensity of the subunit p65 (Figures 3B,F). Finally, western blot
FIGURE 2 | ADA induces apoptosis in metastatic melanoma cells PES43 and A375. PES43 and A375 cells were treated with ADA (100 µM) at different time
points and apoptosis was determined by flow cytometry analysis. Apoptosis was determined by annexin V/propidium iodide (PI) staining, which detects the
externalization of phosphatidylserine (PS). This dual staining distinguishes between unaffected cells (unlabeled; quadrant 3, Q3), early apoptotic cells (annexin V
positive; quadrant 4, Q4), late apoptotic cells (annexin V positive, PI positive; quadrant 2, Q2), and necrotic (PI positive; quadrant 1, Q1). Treatment of PES43 cells
(A) or A375 cells (D) for 24–48–72 h with ADA (100 µM) resulted in a time-dependent induction of apoptosis. (B,E) Quantitative analysis of apoptosis at various time
points showing that at 72 h about 80% of PES43 cells (B) or A375 cells (E) treated with ADA exhibit markers of late apoptosis. Experiments (n = 5) were run in
triplicate. (C,F) Western blot analysis of caspase 3 and PARP in PES43 (C) or A375 cells (F) whole-cell lysates. PES43 or A375 cells were incubated with ADA 100
µM at different time points and at 24 and 48 h cleavage of caspase 3 and of its substrate PARP was observed.
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FIGURE 3 | ADA inhibits NF-κB activation and down-regulates MAPK/ERK and PI3K/AKT pathways in metastatic melanoma cells. Western blot analysis
carried out on the whole-cell extracts obtained from PES43 (A) and A375 (E) cells treated with ADA 100 µM shows an inhibition of IκBα degradation at 30 and 60
min. Nuclear extracts from control and ADA-treated PES43 (B) and A375 (F) cells collected at 3–6–24–48 h were analyzed by Western blot for NF-κB activation as
p65 nuclear translocation. Both cell lines displayed a constitutively high expression of p65 into the nucleus that was reduced by ADA. Western blot analysis of c-FLIP,
XIAP, and Bcl-2 carried out on PES43 (C) and A375 (G) cells treated with ADA 100 µM for 3–6–24–48 h. ADA decreased the expression of all the anti-apoptotic
genes analyzed in both cell lines. Actin and GAPDH were detected as loading control. Experiments (n = 5) were run in triplicate. Western blot analysis of phospho-
and total Akt and phospho- and total ERK in PES43 (D) and A375 (H) cells treated with ADA (100 µM) for 3–6–24–48 h. Both phospho-AKT (p-AKT) and
phospho-ERK (p-ERK) band intensity was time-dependently reduced following treatment with ADA (100 µM). GAPDH was detected as a loading control. Experiments
(n = 5) were run in triplicate.
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analysis showed that ADA markedly decreased the expression of
three anti-apoptotic proteins whose expression is modulated by
the transcriptional activity of NF-κB, (XIAP, c-FLIP, and Bcl-2)
confirming NF-κB involvement (Figures 3C,G).
Effect of ADA on MAPK/ERK and PI3/AKT
Pathways
The Mitogen-Activated Protein Kinase (MAPK)/ERK and the
Phosphoinositide 3-Kinase (PI3K)/AKT pathways are two of
the most frequently deregulated pathways in melanoma (Hodis
et al., 2012). They play an important role in melanoma
development and progression and are involved in the mechanism
of resistance to targeted therapy (Flaherty et al., 2012). As shown
in Figures 3D,H, both phospho-AKT (p-AKT) and phospho-
ERK (p-ERK) band intensity was time-dependently reduced
following treatment with ADA (100 µM).
Effect of ADA on Cells Invasion
To determine whether ADA affected the invasive ability of the
metastatic melanoma cells PES 43 and A375, we performed
cell invasion assays using a transwell system. As shown in
Figures 4A,B, ADA at 10 and 30 µM significantly inhibited the
invasiveness of PES43 cell line by 33 and 63%, respectively (P <
0.01; P < 0.001 vs. control; n= 5). ADA (10–30 µM) produced a
comparable effect on A375 cell line (Figures 4C,D) inhibiting the
invasiveness by 45 and 67% respectively (P < 0.001 vs. control;
n= 5).
ADA Inhibits Metastatic Melanoma In vivo
in Mice
To properly investigate on the role of ADA on melanoma
progression, we exploited a murine model of metastatic
melanoma induced following the injection of the murine
melanoma cells B16/F-10 into the tail vein of C57BL/6J mice.
Groups of mice were treated with different doses of ADA (5 and
50 mg·kg−1, p.o.) while control group received the vehicle only.
Fourteen days after tumor implant, lungs were removed and the
percentage of metastatic affected area was calculated by using
the software Image J. As shown in Figures 5A,B, ADA (5–50
mg·kg−1) caused a dose-dependent reduction of lung metastases.
The higher dose tested e.g., 50 mg·kg−1 reduced the total area of
about 96% (2.74% vs. control 68.1%).
ADA Releases Hydrogen Sulfide
The incubation of ADA 100 µM in aqueous solution in presence
of the nucleophil L-cysteine led to the generation of a time-
related increase in H2S concentration. The rise of the H2S
production reached a steady-state after about 10 min and the
highest concentration of H2S, recorded after 20 min was 5.05 ±
0.04 µM (Figure 6).
DISCUSSION
In the present study, we describe for the first time, the anti-cancer
properties of ADA, a naturally occurring H2S donor, isolated
and purified from Ferula assa-foetida L. Sulfur compounds
contained within vegetables may be chemically or enzymatically
transformed in the human body with subsequent formation
of H2S (Jacob et al., 2008) and their consumption has been
associated to chemopreventive effects (Krasilnikov et al., 2003).
In particular, the garlic-derived organic polysulfide DATS has
been shown to exhibit anticancer activity (Wang et al., 2012).
Furthermore, epidemiological studies have shown that people
assuming a diet rich in cruciferous vegetables (i.e., broccoli
and cabbage) have a minor incidence of breast, lung, prostate,
colon, and bladder cancer (Spitz et al., 2000; Ambrosone
et al., 2004; Tang et al., 2008; Traka et al., 2008). This activity
has been mainly ascribed to the isothiocyanate component
FIGURE 4 | ADA inhibits the invasion of metastatic melanoma cells. ADA (10–30 µM) suppresses PES43 and A375 cell invasion as measured by a transwell
cell invasion assay. Representative field of invasive cells PES43 (A) and A375 (C) on the membrane Average number of invasive cells PES43 (B) and A375 (D) from
triplicate measurements. (**P < 0.01; ***P < 0.001 vs. control [CTRL]).
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FIGURE 5 | ADA inhibits B16 melanoma metastasis in vivo. B16-F10 mouse melanoma cells were injected through the lateral tail vein of C57BL/6J mice (n = 8
per group). ADA (5 or 50 mg·kg−1 ) was given orally to mice; control mice received vehicle only. ADA 5 and 50 mg·kg−1 reduced the metastatic area by 60 and 96%
respectively. (A) Representative macroscopic pictures of mouse lungs, 14 days after inoculation. (B) Histogram with the percentage of metastatic affected area.
abundantly present in these vegetables. Phytochemicals
rich in sulfur, in particular diet-derived compounds, have
therefore been proposed and applied in clinical trials as cancer
chemopreventive/chemotherapeutic agents. These results
along with studies performed using inhibitors of the enzymes
responsible of H2S production have led to hypothesize a role
for this metabolic pathway in cancer as recently reviewed
(Szabo, 2016). We have previously established that sulfurated
compounds can inhibit human melanoma cell proliferation
(Panza et al., 2015). Here we describe the anti-tumoral activity
of a newly identified natural H2S-donor from Ferula assa-
foetida L. Interestingly, among all the compounds screened
only the non-sulfur containing methoxylatifolone resulted
inactive. This evidence further support our working hypothesis
that the presence of sulfur is required in order to display
anti-proliferative activity in melanoma. Indeed, all the sulfur
containing compounds isolated were active on A375 melanoma
cells and, among these, ADA and PDA showed the highest
potency. ADAwas selected to perform the study for the following
reasons: (i) it displayed a clear concentration-dependent effect, as
opposite to PDA that appeared to have a threshold concentration;
(ii) it was the most abundant vinyl disulfide present in Ferula
assa-foetida. The latter aspect has to be outlined since the
abundance of a purified natural compound makes it possible to
perform amore in deep and accurate pharmacological evaluation
of its biological activities. Thus, we further investigated on ADA
activity by using a panel of melanoma cell lines. Among the
human cells tested, the metastatic cell lines PES 43 and A375
resulted themost sensible to the anti-proliferative activity ofADA
and thus were selected for the mechanistic studies. Since in many
cases the anti-proliferative effect of H2S-releasing molecules
is related to their ability to activate the apoptotic machinery
we investigated on this biochemical event performing flow
citometry and western blot analysis on both cell lines. The results
confirmed that ADA anti-proliferative effect relies on induction
of apoptosis. This was confirmed by the cytofluorimetric assay
with Annexin V/PI dual staining and by the time-dependent
cleavage of caspase 3 and of its substrate PARP. In order to
better understand the mechanism(s) underlying the apoptotic
effect we investigated on the downstream signaling, looking
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FIGURE 6 | ADA releases hydrogen sulfide. Curve describes the increase
of H2S concentration, with respect to time, following the incubation of ADA
(100 µM) in the assay buffer in the presence of the nucleophile L-cysteine.
H2S was recorded by amperometry; the vertical bars indicate the SEM.
at a possible involvement of NF-κB. Indeed, this pleiotropic
transcription factor plays important roles in controlling cell
proliferation, apoptosis, and oncogenesis. NF-κB activation
has been also shown to promote melanoma tumor progression
(Richmond, 2002; Ivanov et al., 2003). In fact, in late melanoma
stage, NF-κB is up-regulated and inhibits cell apoptosis by
enhancing the expression of several anti-apoptotic genes such
as XIAP (Deveraux et al., 1998), c-FLIP (Micheau et al., 2001),
and BclxL genes (Ravi et al., 2001). In most non-transformed
cell types, NF-κB complexes bound to an inhibitor, IκB, are
largely cytoplasmic. On activation, the IκB proteins become
phosphorylated, ubiquitinated, and subsequently degraded.
Freed NF-κB accumulates in the nucleus, where it enhances the
transcription of specific genes. We demonstrated, by western
blot analysis, that ADA inhibited both the phosphorylation and
degradation of IkBα thereby preventing the nuclear translocation
of the p65 subunit containing the transcriptional activation
domain. The involvement of NF-κB was further supported
by the finding that the expression of the anti-apoptotic genes
c-FLIP, XIAP and Bcl-2 was also reduced. Indeed, all these three
genes are transcriptionally regulated by NF-κB. As well as for
NF-κB also the serine/threonine kinase Akt is constitutively
activated in human melanomas (Madhunapantula et al., 2011).
Although it may not be essential for initiation of melanoma,
Akt activation facilitates melanoma progression by enhancing
cell survival through up-regulation of NF-κB (Dhawan et al.,
2002). Our results clearly show that ADA down-regulates Akt
activity by reducing the phosphorylation on Ser473. Therefore,
ADA inhibits the constitutive activated PI3K/Akt pathway and
its downstream target NF-κB in melanoma cells.
Another key player involved in melanoma progression and
resistance to current therapies is the Ras/Raf/MAPK pathway
that is strictly linked to Akt pathway (Dhillon et al., 2007;
Sullivan and Flaherty, 2013). In fact, several new drugs
interfering with these two pathways are in advanced clinical
phase for the treatment of resistant metastatic melanoma.
Our results demonstrated an inhibitory effect of ADA also on
the Ras/Raf/MAPK pathway. In fact, following incubation of
melanoma cells with ADA, we observed a reduction of the
phosphorylation and activation of ERK1/2. The dual inhibitory
effect exhibited by ADA on both activating pathways is in
line with the therapeutic strategy that are currently clinically
explored in melanoma. It is well-known that mutant B-RAF
may indirectly activate NF-κB through constitutive activation of
the downstream effector protein ERK1/2 and the up-regulation
of inflammatory cytokines leading to increases in survival,
proliferation and invasiveness (Norris and Baldwin, 1999). In
particular the increased ability of cancer cells to invade adjacent
tissues is one of the critical steps leading to metastasis (Chaffer
and Weinberg, 2011). This process is poorly understood even
if it is the major cause of cancer-related mortality. Therefore,
many investigators are trying to find strategies to suppress tumor
growth as well as tumor metastasis. We addressed this particular
issue by performing in vitro and in vivo experiments. Firstly,
we demonstrated that ADA inhibits melanoma cells invasive
capability in vitro by almost 70% at the higher dose used. All these
in vitro evidence clearly indicated that ADA, by interfering with
more than one mechanism involved in melanoma progression
and spreading, has the potential to act also in vivo. In order to
address this issue we used a model of pulmonary metastasis in
mice that mimic the common and virulent phenomena of human
metastasis and is widely used for the pre-clinical evaluation of
drugs (Overwijk and Restifo, 2001). The injection ofADA to mice
significantly suppressed (about 96% as compared to untreated
mice) metastatic tumor growth in the lung suggesting that ADA
reduced migration and growth of melanoma cancer cells in lung
tissue. Of particular interest is the fact that the anti-tumor effect
displayed by ADA is more sustained of that displayed by the
well-characterized H2S-releasing molecule DATS (Panza et al.,
2015).
It is necessary to point out that B16-F10, as any tumor cells,
once injected intravenously migrate into the lungs. Therefore,
the term pulmonary metastasis is widely used even though
every resulting pulmonary nodule is technically an independent
“primary” tumor rather than a true metastasis (Overwijk and
Restifo, 2001). Nevertheless, within the limit of this preclinical
model, ADA also in vivo displayed a significant and marked
anticancer activity.
A recent investigation has reported a detailed picture of
the sulfur-containing compounds of asafoetida. These mixed
S-alkyl-S-alkenyldisulfides are able to release H2S due to
their electrophilic nature and tendency to react with different
nucleophilic (Nu:) agents (Shokoohinia et al., 2013).
In conclusion, we have established that ADA, a sulfur-
containing compound of asafetida, not only suppresses
melanoma cell growth and tumor cell migration in vitro but it
is also active in vivo. Metastasis in cancer patients is associated
with poor prognosis and death. Therefore, the finding of new
strategies to suppress tumor growth and tumor metastasis is an
unmet clinical need. The results of our study point toward this
aim indicating ADA as a lead compound for the development of
a new class of drugs active in metastatic melanoma based on the
presence of labile sulfur in their structure.
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